International Registry of Flow Diverter Stents (IRF) (IRF)
Resultater af flowdiverters til behandling af intrakranielle aneurismer - International Registry of Flow Diverter Stents (IRF)
This multicenter retrospective cohort study aims to evaluate and compare the technical performance, safety, and clinical outcomes of intracranial aneurysms treated with flow diverter stents and endosaccular flow disruptors.
Studieoversigt
Status
Status
Betingelser
Betingelser
Detaljeret beskrivelse
Flow diverters and endosaccular flow disruptors used for the treatment of intracranial aneurysms exhibit distinct procedural and clinical outcomes, with potential differences in device-specific parameters such as procedure time, radiation exposure, adjunct device requirements, and long-term angiographic success. Since the completion of the Pipeline Embolization Device (PED) for the Intracranial Treatment of Aneurysms trial, the field of flow diversion has undergone continuous evolution with the development and approval of several devices. While these devices share a similar mechanism for aneurysm occlusion, their design and delivery systems can vary significantly. Various studies have demonstrated a promising safety and efficacy profile; however, the available data for a direct comparison of the technical and clinical outcomes between these devices remains limited.
The following collaborator is also involved in the research:
Name: Muhammed Amir Essibayi Email: m.amir.essibayi@gmail.com
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Muhammed Amir Essibayi, MD
- Telefonnummer: 347-908-1889
- E-mail: Muhammedamir.essibayi@einsteinmed.edu
Studiesteder
-
-
Ontario
-
Toronto, Ontario, Canada, M5B 1W8
- Rekruttering
- St. Michael's Hospital
-
Ledende efterforsker:
- Vitor Mendes Pereira, MD
-
Kontakt:
- Vitor Mendes Pereira, MD
- Telefonnummer: 416-864-5131
- E-mail: PereiraReferrals@unityhealth.to
-
Kontakt:
- Eileen Liu, MSc
- E-mail: eileen.liu@unityhealth.to
-
Toronto, Ontario, Canada, M5T 2S8
- Rekruttering
- Toronto Western Hospital
-
Kontakt:
- Pascal Mosimann, MD, PD
- Telefonnummer: 416-603 5800
- E-mail: pascal.mosimann@uhn.ca
-
Ledende efterforsker:
- Pascal Mosimann, MD, PD
-
-
-
-
Florida
-
Coral Gables, Florida, Forenede Stater, 33146
- Rekruttering
- University of Miami
-
Kontakt:
- Robert M Starke, MD, MS
- Telefonnummer: 305-355-1101
- E-mail: RStarke@med.miami.edu
-
Ledende efterforsker:
- Robert M Starke, MD, MS
-
Jacksonville, Florida, Forenede Stater, 32224
- Afsluttet
- Mayo Clinic Florida
-
Sarasota, Florida, Forenede Stater, 34239
- Afsluttet
- Sarasota Memorial Research Institute
-
-
Massachusetts
-
Burlington, Massachusetts, Forenede Stater, 01805
- Rekruttering
- Lahey Hospital and Medical Center
-
Kontakt:
- Timo Krings, MD, PhD, MSc
- Telefonnummer: 781-744-3330
- E-mail: Timo.Krings@lahey.org
-
Ledende efterforsker:
- Timo Krings, MD, PhD, MSc
-
-
Michigan
-
Traverse City, Michigan, Forenede Stater, 49684
- Rekruttering
- Munson Medical Center
-
Kontakt:
- Amy Peterson, PhD
- Telefonnummer: 231-935-6746
- E-mail: apeterson4@mhc.net
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55404
- Rekruttering
- Allina Health
-
Kontakt:
- Collin M Torok, MD
- Telefonnummer: 612-863-0376
- E-mail: collin.torok@allina.com
-
Kontakt:
- Marie Meyer, MA
- E-mail: marie.meyer@allina.com
-
Ledende efterforsker:
- Collin M Torok, MD
-
-
New Jersey
-
New Brunswick, New Jersey, Forenede Stater, 08901
- Rekruttering
- Robert Wood Johnson University
-
Ledende efterforsker:
- Gaurav Gupta, MD
-
Kontakt:
- Gaurav Gupta, MD
- Telefonnummer: 732-235-6333
- E-mail: guptaga@rwjms.rutgers.edu
-
-
New York
-
Buffalo, New York, Forenede Stater, 14068
- Afsluttet
- University at Buffalo
-
The Bronx, New York, Forenede Stater, 10467
- Rekruttering
- Montefiore Medical Center Department of Neurosurgery
-
Ledende efterforsker:
- David Altschul, MD
-
Kontakt:
- Muhammed Amir Essibayi, MD
- Telefonnummer: 347-908-1889
- E-mail: Muhammedamir.essibayi@einsteinmed.edu
-
Kontakt:
- David Altschul, MD
- Telefonnummer: (718) 920-7498
- E-mail: daltschu@montefiore.org
-
-
Pennsylvania
-
Danville, Pennsylvania, Forenede Stater, 17822
- Afsluttet
- Geisinger Health
-
-
Texas
-
Kingwood, Texas, Forenede Stater, 77339
- Afsluttet
- HCA Houston Healthcare Kingwood
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Patients with intracranial aneurysms who underwent endovascular treatment with flow diverter stents or endosaccular flow disruptors
Beskrivelse
Inclusion Criteria:
-
Consecutive adult patients (18 years of age or older)
-
Underwent endovascular treatment with one of the following devices:
a. Endoluminal Flow Diverter Stents: i. Pipeline Flex (Covidien, California, USA) ii. Pipeline Flex with Shield Technology (Covidien) iii. Surpass Streamline (Stryker Neurovascular, California, USA) iv. Surpass Evolve (Stryker) v. Silk flow diverter (Balt Extrusion, Montmorency, France) vi. Flow-Redirection Intraluminal Device (FRED; MicroVention) vii. Flow-Redirection Intraluminal Device X (FRED X; MicroVention) viii. p64 Flow Modulation Device (phenox GmbH) ix. Endovascular clip system (eCLIPs) (eCLIPsTM, eVasc Neurovascular, Vancouver, BC, Canada)
b. Intrasaccular Flow Disruptors: i. Woven EndoBridge (WEB; MicroVention) ii. Luna/Artisse System (Medtronic) iii. Medina Embolic Device (Medtronic) iv. Contour Neurovascular System (Cerus Endovascular) v. Neqstent Coil Assisted Flow Diverter (Cerus Endovascular) vi. pCONus and pCANvas (phenox GmbH) vii. Nexus Aneurysm Embolization System (EndoStream Medical) viii. CITADEL™ Embolization Device (Balt, USA)
-
Complete medical records and follow-up data available
Exclusion Criteria:
- Incomplete procedural or follow-up records
- Non-flow-diverter or non-flow-disruptor treatments (e.g., coiling-only cases)
- Aneurysms treated with investigational devices not listed within Inclusion Criteria
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: RETROSPECTIVE
Antal grupper/kohorter
Kohorter og interventioner
Gruppe / kohorteGruppe / kohorte |
|---|
|
Endoluminal Flow Diverter Stent
Adults with intracranial aneurysms treated with an endoluminal flow diverter stent as part of routine care. |
|
Intrasaccular Flow Disruptor
Adults with intracranial aneurysms treated with an intrasaccular flow disruptor as part of routine care. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Technical Success
Tidsramme: Periprocedurally, up to 24 hours
|
Technical Success will be determined by successful deployment of the flow diverter stent or endosaccular flow disruptors. A dichotomous determination (i.e., Yes/No) will be made and summarized for this study. |
Periprocedurally, up to 24 hours
|
|
Procedural Complications following placement
Tidsramme: From the time of the procedure up to 1 month post treatment
|
Procedural complications will be identified as the number of instances of the following adverse clinical events: In-stent Thrombosis/Stenosis; Ischemic complications (Transient Ischemic Attack/Stroke), Intracerebral hemorrhage, Aneurysm rupture, and Vessel occlusion due to flow diverter stent or endosaccular flow disruptor placement. |
From the time of the procedure up to 1 month post treatment
|
|
Clinical Outcomes at Discharge
Tidsramme: Upon study discharge, up to 4 weeks
|
Clinical outcomes at discharge will be assessed using the modified Rankin Scale (mRS) for neurologic disability. The mRS is a 6-point disability scale with possible scores ranging from 0-5. mRS measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. Higher scores are generally associated with less favorable outcomes. For this study patients with an mRS score of 0-2 will be determined to have had a "favorable" outcome to the procedure and patients with an mRS score of 3-5 will have been determined to have had an "unfavorable" outcome. |
Upon study discharge, up to 4 weeks
|
|
Clinical Outcomes at last available Follow-up
Tidsramme: Up to 24 months post procedure
|
Clinical outcomes at last available follow-up will be assessed using a variant of the modified Rankin Scale (mRS) for neurologic disability. The classic mRS is a 6-point disability scale with possible scores ranging from 0-5. mRS measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. Higher scores are generally associated with less favorable outcomes. For this study patients with an mRS score of 0-2 will be determined to have had a "favorable" outcome to the procedure and patients with an mRS score of 3-5 will have been determined to have had an "unfavorable" outcome. Scoring will also include a 6 to identify patients who have expired. |
Up to 24 months post procedure
|
|
Immediate Angiographic Outcomes at Discharge - O'Kelly-Marotta (OKM) grading scale
Tidsramme: Upon study discharge, up to 4 weeks
|
Immediate Angiographic Outcomes at Discharge will be evaluated using the OKM grading scale. The OKM scale will be used to assess the degree of angiographic filling and in the setting of intracranial aneurysms which were treated by endovascular flow diversion. It is used to predict aneurysm closure over time. Patient outcomes will be stratified based on the following scale scores: Grade A: Total filling (>95% of aneurysm remained); Grade B: Subtotal filling (5-95% of aneurysm remained); Grade C: Entry remnant (<5% aneurysm remained); and Grade D: No filling (0% aneurysm remained). As such, the less aneurysm remnant the more favorable the angiographic outcome. The number/percentage of cases of each OKM Grade will be summarized. |
Upon study discharge, up to 4 weeks
|
|
Immediate Angiographic Outcomes at Discharge - Modified Raymond-Roy Classification (mRRC)
Tidsramme: Upon study discharge, up to 4 weeks
|
Immediate Angiographic Outcomes at Discharge will also be evaluated using mRRC categorization. mRRC categorization will be used to assess the degree of occlusion achieved when treating an intracranial aneurysm. It categorizes the level of residual contrast filling within an aneurysm after coiling. For purposes of this analysis, Class I will signify complete occlusion; Class II will signify Residual neck occlusion; Class IIIa will signify Residual aneurysm with contrast stasis; and Class IIIb will signify Residual aneurysm without contrast stasis. As such, it is an indicator of how effectively the aneurysm has been sealed off during treatment. The number/percentage of cases of each mRRC category will be summarized. |
Upon study discharge, up to 4 weeks
|
|
Immediate Angiographic Outcomes at Discharge - WEB Occlusion Scale (WOS)
Tidsramme: Upon study discharge, up to 4 weeks
|
Immediate Angiographic Outcomes at Discharge will be evaluated using the WOS grading scale. The WOS is a standardized angiographic assessment scale for reporting aneurysm occlusion achieved with endosaccular flow disruptors and can be employed to assess the adequacy of treatment. For purposes of this analysis, WOS Grade A will signify complete occlusion; WOS Grade B will signify Residual neck occlusion; and WOS Grade C will signify Residual aneurysm filling. The number/percentage of cases of each WOS grade category will be summarized. |
Upon study discharge, up to 4 weeks
|
|
Angiographic Outcomes at last available Follow-up - O'Kelly-Marotta (OKM) grading scale
Tidsramme: Up to 24 months post procedure
|
Immediate Angiographic Outcomes at Discharge will be evaluated using the OKM grading scale. The OKM scale will be used to assess the degree of angiographic filling and in the setting of intracranial aneurysms which were treated by endovascular flow diversion. It is used to predict aneurysm closure over time. Patient outcomes will be stratified based on the following scale scores: Grade A: Total filling (>95% of aneurysm remained); Grade B: Subtotal filling (5-95% of aneurysm remained); Grade C: Entry remnant (<5% aneurysm remained); and Grade D: No filling (0% aneurysm remained). As such, the less aneurysm remnant the more favorable the angiographic outcome. The number/percentage of cases of each OKM Grade will be summarized. |
Up to 24 months post procedure
|
|
Angiographic Outcomes at last available Follow-up - Modified Raymond-Roy Classification (mRRC)
Tidsramme: Up to 24 months post procedure
|
Immediate Angiographic Outcomes at Discharge will also be evaluated using mRRC categorization. mRRC categorization will be used to assess the degree of occlusion achieved when treating an intracranial aneurysm. It categorizes the level of residual contrast filling within an aneurysm after coiling. For purposes of this analysis, Class I will signify complete occlusion; Class II will signify Residual neck occlusion; Class IIIa will signify Residual aneurysm with contrast stasis; and Class IIIb will signify Residual aneurysm without contrast stasis. As such, it is an indicator of how effectively the aneurysm has been sealed off during treatment. The number/percentage of cases of each mRRC category will be summarized. |
Up to 24 months post procedure
|
|
Angiographic Outcomes at last available Follow-up - WEB Occlusion Scale (WOS)
Tidsramme: Up to 24 months post procedure
|
Immediate Angiographic Outcomes at Discharge will be evaluated using the WOS grading scale. The WOS is a standardized angiographic assessment scale for reporting aneurysm occlusion achieved with endosaccular flow disruptors and can be employed to assess the adequacy of treatment. For purposes of this analysis, WOS Grade A will signify complete occlusion; WOS Grade B will signify Residual neck occlusion; and WOS Grade C will signify Residual aneurysm filling. The number/percentage of cases of each WOS grade category will be summarized. |
Up to 24 months post procedure
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Radiation Exposure
Tidsramme: Periprocedurally, up to 4 hours
|
Radiation exposure over the course of the procedure will be extracted and summarized. Radiation exposure will be evaluated based on relevant imaging system metrics used to calculate the total radiation dose delivered to the patient based on the fluoroscopy time and the area of the X-ray field exposed during the procedure. Flow diverter stents and endosaccular flow disruptors typically result in significantly lower radiation exposure compared to other endovascular techniques for treating brain aneurysms due to a reduction in fluoroscopy time and overall reduced radiation dose due to the streamlined nature of the procedures. |
Periprocedurally, up to 4 hours
|
|
Procedure Duration
Tidsramme: Periprocedurally, up to 4 hours
|
The duration of procedure placement will be extracted and summarized. The duration of the procedure is influenced by the complexity of the aneurysm, the patient's anatomy, and the experience of the interventional radiologist and care team. Shorter procedure duration times are associated with more favorable outcomes. |
Periprocedurally, up to 4 hours
|
|
Use of Adjunct Devices
Tidsramme: Periprocedurally, up to 4 hours
|
The use of adjunctive devices such as coils, stents or balloons to further enhance aneurysm occlusion of the flow diverter stent or to facilitate positioning and deployment of the endosaccular flow disruptor within the aneurysm sac during the procedure will be extracted and summarized. The number of adjunct devices will be extracted and summarized. |
Periprocedurally, up to 4 hours
|
|
Recurrence of Aneurysm
Tidsramme: 6 to 24 months post procedure
|
The percentage of patients who experienced aneurysm recurrence will be extracted and summarized based on a binary (Yes/No) determination following retrospective record review. The span of time from initial treatment to recurrence will be assessed and summarized. |
6 to 24 months post procedure
|
|
Aneurysm Retreatment
Tidsramme: 6 to 24 months post procedure
|
The percentage of patients who required retreatment for a recurrence of aneurysm will be extracted and summarized based on a binary (Yes/No) determination following retrospective record review. The span of time from initial treatment to retreatment will be assessed and summarized. |
6 to 24 months post procedure
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: David Altschul, MD, Montefiore Medical Center
Publikationer og nyttige links
Generelle publikationer
- Nelson PK, Lylyk P, Szikora I, Wetzel SG, Wanke I, Fiorella D. The pipeline embolization device for the intracranial treatment of aneurysms trial. AJNR Am J Neuroradiol. 2011 Jan;32(1):34-40. doi: 10.3174/ajnr.A2421. Epub 2010 Dec 9.
- Hecker C, Broussalis E, Griessenauer CJ, Killer-Oberpfalzer M. A mini-review of intrasaccular flow diverters. J Neurointerv Surg. 2023 Jan;15(1):70-74. doi: 10.1136/neurintsurg-2021-018426. Epub 2022 May 17.
- Colby GP, Lin LM, Caplan JM, Jiang B, Michniewicz B, Huang J, Tamargo RJ, Coon AL. Flow diversion of large internal carotid artery aneurysms with the surpass device: impressions and technical nuance from the initial North American experience. J Neurointerv Surg. 2016 Mar;8(3):279-86. doi: 10.1136/neurintsurg-2015-011769. Epub 2015 May 18.
- Vivanco-Suarez J, Feigen C, Javed K, Dardick JM, Holland R, Mendez-Ruiz A, Ortega-Gutierrez S, Haranhalli N, Altschul DJ. Dataset on flow diversion procedures performed with the Pipeline Embolization Device, Pipeline Flex, and Surpass Streamline for intracranial aneurysms. Data Brief. 2022 May 21;42:108299. doi: 10.1016/j.dib.2022.108299. eCollection 2022 Jun.
- Wakhloo AK, Lylyk P, de Vries J, Taschner C, Lundquist J, Biondi A, Hartmann M, Szikora I, Pierot L, Sakai N, Imamura H, Sourour N, Rennie I, Skalej M, Beuing O, Bonafe A, Mery F, Turjman F, Brouwer P, Boccardi E, Valvassori L, Derakhshani S, Litzenberg MW, Gounis MJ; Surpass Study Group. Surpass flow diverter in the treatment of intracranial aneurysms: a prospective multicenter study. AJNR Am J Neuroradiol. 2015 Jan;36(1):98-107. doi: 10.3174/ajnr.A4078. Epub 2014 Aug 14.
- O'kelly CJ, Krings T, Fiorella D, Marotta TR. A novel grading scale for the angiographic assessment of intracranial aneurysms treated using flow diverting stents. Interv Neuroradiol. 2010 Jun;16(2):133-7. doi: 10.1177/159101991001600204. Epub 2010 Jul 19.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 2023-15177
- 2023 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .